Finance

Lists
ALGS:NASDAQ
Aligos Therapeutics Inc
$5.53
-0.18%
(-0.0100) 1D
Sep 29, 10:51:37 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALGS...
Open
$5.53
High
$5.54
Low
$5.52
Mkt. cap
34.53M
Avg. vol.
57.82K
Volume
965.00
52-wk high
$13.69
52-wk low
$3.98
EPS
-$7.31
Beta
2.34
Shares outstanding
5.44M
No. of employees
82
Open
$5.53
High
$5.54
Low
$5.52
Mkt. cap
34.53M
Avg. vol.
57.82K
Volume
965.00
52-wk high
$13.69
52-wk low
$3.98
EPS
-$7.31
Beta
2.34
Shares outstanding
5.44M
No. of employees
82
News stories
From web sources and news partners
About Aligos Therapeutics Inc
CEO-
Employees82
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitealigos.com
Analyst ratings
Based on 4 analysts giving stock ratings to ALGS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ALGS in the last 3 months.
Highest
Current $5.53
$175.00 (+3,064.56%)
Average
$72.50 (+1,211.03%)
Lowest
$20.00 (+261.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$50.00
+804.2%
08/10/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$175.00
+3,064.6%
08/07/2026
Daniel Brims
Lake Street
Buy
Reiterated
$45.00
+713.7%
08/07/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$20.00
+261.7%
08/06/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
$20.00
+261.7%
05/21/2026
Anthea Li
Jefferies
Buy
Initiated
$48.00
+768%
03/19/2026
Unknown Analyst
Jefferies
Buy
Initiated
$48.00
+768%
03/19/2026
Michael Yee
UBS
Buy
Maintained
$20.00
+261.7%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
741.00K
169.00K
2.83M
27.78M
Cost of goods sold
23.94M
17.04M
666.00K
24.05M
Cost of revenue
23.94M
17.04M
666.00K
24.05M
Research and development expenses
-
-
22.69M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.16M
4.94M
6.41M
5.62M
Operating expense
5.16M
4.94M
29.09M
5.62M
Total operating expenses
29.10M
21.98M
29.76M
29.67M
Operating income
-28.36M
-21.81M
-26.93M
-1.89M
Other non operating income
-3.50M
1.22M
4.07M
2.95M
EBT including unusual items
-31.48M
-19.85M
-22.72M
1.31M
EBT excluding unusual items
-31.48M
-19.85M
-22.72M
1.31M
Income tax expense
56.00K
30.00K
317.00K
2.81M
Effective tax rate
-0.18%
-0.15%
-1.40%
215.07%
Other operating expenses
-
-
-
-
Net income
-31.54M
-19.88M
-23.04M
-1.50M
Net profit margin
-4,256.01%
-11,763.91%
-814.13%
-5.41%
Earnings per share
-3.04
-1.91
-2.21
-0.14
Interest and investment income
378.00K
548.00K
140.00K
246.00K
Interest expense
-
-
-
-
Net interest expenses
378.00K
548.00K
140.00K
246.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.14M
-21.56M
-26.58M
-1.64M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps